Injectable Male Birth Control Effective for at Least 2 Years, Says Biotech Startup

Today, almost all available birth control options are female contraceptives. Biotech claims that clinical trials have reached a critical stage for the contrast, hormonal and returned male contraceptive.

One News Today, the Convalame, Adam, proved to be effective and safe in the first man’s clinical trial of Adam. Although their clinical results are not yet broadcast in a scientific magazine, the company plans to spread additional information at the American Urological Association (AUA) in April 26.

The man is a hydrojel that solves a water-solving water – two pipes in two pipes in men carrying sperm from testicles through a small procedure. The implant blocks the sperm when it still allows you to discharge, and the contrast is in the future, in the future, in accordance with long-term, returning alternative and returning alternatives.

“Our goal was to create a contraining option for a two-year-old man, which responded directly to the consumer needs,” Alexander Pastuszak, the General Medical Officer, said he was released. “These findings confirm that our roman water-soluble hydrogle can achieve Adam’s life.

Milestone is based on two participants in the first person’s clinical judgment in Azoospermia (no unloaded sperm) for 24 months. One Release of previous newsContral claimed that Adam caused up to 99.8% to 100% of the number of sperm moving within the implantation.

These results “a step to change the contraceptive landscape,” Kevin Eisenfrass, co-founder and the General Director of the Control, then said. They suggest that this also suggests that it is possible to achieve the level of efficiency as relevant women’s contraceptives as IUDS. Iuds, or Intrauterine devicesSmall women entered in the uterus are contraceptive devices.

None of the participants reported for the issuance of the latest news Serious adverse eventsor faced an unexpected safety concern. The clinical trial researchers will continue to monitor other participants with a laboratory and a laboratory in 12-18-18, 18-12 and 21-month-old. In addition, the control confirmed the full regulation to start the second stage of the study.

However, a professor Jon Oatley, a professor at the Molecular Bioskance School of Washington State University, said that there are no public information confirming the conversion of the man and researchers still did not know the long-term effects of Vasa postponement Guardian. Oatley also suggested that most men would prefer a contraceptive pill from a surgery or transaction.

But From 2017 since 2019 10.4% of women aged 15 and 49, for example, used a long-term backpacking contraceptive such as IUDS or other contraceptive implants. 14% of this pill are less than four points behind. If Adam proves that it is really safe and effective, perhaps a large number of men will choose more injection effectiveness than other contraceptives.